Peptide Atlas — health, wellness & peptide resources
Peptide Library
Recovery & Tissue Research

BPC-157

Also referenced as: Body Protection Compound-157, PL 14736, pentadecapeptide BPC 157

The most discussed recovery peptide in wellness culture, and one of the clearest examples of a preclinical evidence base being read as clinical proof.

Evidence grade
DPreclinical Research

Preclinical Research

Regulatory status
Not FDA Approved

Not approved for any indication. In the United States it was placed on the FDA's list of substances difficult to compound, and it is prohibited in sport under WADA rules.

Human data
Limited

No registered clinical trials identified

Last reviewed
September 1, 2026

Overview

BPC-157 is a synthetic 15-amino-acid sequence related to a fragment of human gastric juice protein BPC. Animal research has reported accelerated healing across tendon, muscle, gut, bone and nerve injury models.

The gap between that preclinical literature and human evidence is wide. Enthusiasm in fitness and longevity communities substantially exceeds what published human data can support.

Why It's Being Studied

  • Tendon, ligament and muscle healing after injury in animal models.
  • Gastrointestinal mucosal protection, including inflammatory bowel models, where early human work has been directed.
  • Angiogenesis and nerve regeneration questions.

Mechanism of Action

In plain language

In animals it appears to help new blood vessels and connective tissue form at an injury site, which speeds healing in those models.

Technical detail

Proposed mechanisms include upregulation of VEGF receptor 2 signalling and the FAK-paxillin pathway, modulation of nitric oxide systems, effects on growth hormone receptor expression in tendon fibroblasts, and interaction with the gut-brain axis. Most mechanistic work is rodent or in-vitro.

Research Areas & Routes Studied

Areas studied
  • Tendon and ligament healing
  • Muscle injury
  • Gastrointestinal mucosa
  • Angiogenesis
  • Nerve injury
Routes used in research
  • Subcutaneous injection (animal research)
  • Intraperitoneal (animal research)
  • Oral (animal research)

Evidence Summary

A large volume of animal research, much of it from a small number of research groups, with essentially no completed and published randomised human trials.

Human clinical evidence

  • Early-phase work in inflammatory bowel disease has been reported, but no adequately powered, published randomised trials establish efficacy for tendon, joint or muscle healing in people.

Animal studies

  • Numerous rat and mouse studies report faster healing of tendon, muscle, gut, bone and nerve injuries.
  • A large share of this literature originates from a small number of affiliated research groups, which limits independent replication.

In-vitro studies

  • Fibroblast and endothelial cell studies describing migration and growth factor signalling.

Anecdotal / community information

  • Extensive first-person injury-recovery reports. These are uncontrolled, unblinded and cannot distinguish healing from natural recovery.

Reported Adverse Events in Research

  • No systematic human safety dataset exists. Reported tolerability comes from animal studies and uncontrolled human reports.
  • Because it promotes angiogenesis in animal models, its behaviour in the presence of undiagnosed malignancy is an open safety question.
  • Research-use-only material carries independent risks of misidentification, contamination and incorrect concentration.

Limitations of Current Evidence

  • Preclinical dominance: animal healing models are poor predictors of human musculoskeletal outcomes.
  • Limited independent replication of the core findings.
  • No established human dosing protocol exists.

Documented Research Protocols

  • BPC-157 — research context, not a human protocol

    Set out what published research does and does not establish about BPC-157 administration, and why no human protocol can responsibly be summarised.

    View documented protocol

Why It Is Used

  • Recovery

    Soft-Tissue Injury and Recovery

    BPC-157 is the single most searched research peptide. The gap between how confidently it is discussed and what has been published in humans is the story here.

    Read the case study

Research References

  • Narrative review

    Stable gastric pentapeptide BPC 157: tissue healing research review

    Sikiric P, et al.
    Main finding
    Summarises reported healing effects across multiple animal injury models.
    Limitations
    Review authored by the principal research group; not independent evidence and not human evidence.
    View Study
  • Animal study

    BPC 157 in tendon healing (animal model)

    View Study
  • Regulatory document

    FDA compounding category 2 bulk drug substances list

    Main finding
    BPC-157 appears among substances identified as raising significant safety risks in compounding.
    View Source
This page is an educational research summary. It is not medical advice, does not recommend human use, and does not provide individualised dosing. Many compounds discussed here are research use only and are not approved medicines.